ClinicalTrials.gg
TerminatedNCT03140722Updated Feb 21, 2021Results posted

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

A Phase 2 interventional study of vadadustat and epoetin alfa in Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Revised study design.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
24th of 27
2 · median 60
Started
2017
with 2 others
Phase 2
8 of 27
none open now
Registered
14th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 24th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 14th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)

03

Conditions studied

  • Anemia
  • Dialysis-Dependent Chronic Kidney Disease

Browse trials for

Keywords

  • anemia
  • kidney
  • dialysis-dependent chronic kidney disease
  • CKD
  • DD-CKD
  • renal
  • vadadustat
  • AKB-6548
  • hypoxia-inducible factor
  • HIF
  • hypoxia-inducible factor prolyl-hydroxylase inhibitor
  • HIF-PHI
  • hyporesponder
  • hyporesponsive
  • epoetin alfa
  • hemoglobin
  • erythropoiesis stimulating agent
  • ESA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥18 years of age
  • Receiving chronic maintenance hemodialysis for end-stage kidney disease
  • Currently receiving epoetin alfa for anemia
  • between 8.5 and 10.0 g/dL during screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss
  • Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
  • Red blood cell transfusion within 4 weeks prior to or during screening
  • Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    vadadustat

    Vadadustat daily oral dose, adjustable based on Hb level

    Drug: vadadustat

  • Active comparator
    epoetin alfa

    Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study

    Drug: epoetin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hb) Over Time During the Treatment Period

    Time frame: Baseline; up to 20 weeks

Secondary outcomes

  1. Number of Participants Demonstrating Incremental Increases in Hb From Baseline Over Time During the Treatment Period

    Time frame: Baseline; up to 20 weeks

  2. Number of Participants With Hb Values Within the Target Range of 10.0-11.0 Grams Per Deciliter (g/dL) During the Treatment Period

    Time frame: Baseline; up to 20 weeks

  3. Number of Participants Receiving Epoetin Alfa Rescue

    Time frame: up to 20 weeks

  4. Number of Participants Receiving Red Blood Cell Transfusion

    Time frame: up to 20 weeks

  5. Number of Participants With Specified Levels of Various Biomarkers, Including C-reactive Protein, Hepcidin, and Vascular Endothelial Growth Factor

    Time frame: up to 20 weeks

  6. Mean Weekly Dose of Intravenous Elemental Iron Administered

    Time frame: up to 20 weeks

  7. Number of Participants Maintaining Iron Sufficiency (Defined as Ferritin ≥100 Nanograms Per Milliliter and Transferrin Saturation ≥20%)

    Time frame: up to 20 weeks

  8. Number of Participants Utilizing Resources

    Time frame: up to 20 weeks

  9. Number of Participants With Treatment-emergent Adverse Events

    Treatment-emergent adverse events were collected in all participants enrolled in the study.

    Time frame: up to 24 weeks

07

Results

Posted Feb 21, 2021
Limitations and caveats
The Study was closed by the Sponsor as it was determined that it was more appropriate to initiate a new study that would explore the broader population utilizing a modified dosing approach (rather than amending the current protocol design).

Participant flow

Participant flow — Overall Study
MilestoneVadadustatEpoetin Alfa
Started02
Completed02
Not completed00

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hb) Over Time During the Treatment Period
Time frame:
Baseline; up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Demonstrating Incremental Increases in Hb From Baseline Over Time During the Treatment Period
Time frame:
Baseline; up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Hb Values Within the Target Range of 10.0-11.0 Grams Per Deciliter (g/dL) During the Treatment Period
Time frame:
Baseline; up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Receiving Epoetin Alfa Rescue
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Receiving Red Blood Cell Transfusion
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Specified Levels of Various Biomarkers, Including C-reactive Protein, Hepcidin, and Vascular Endothelial Growth Factor
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryMean Weekly Dose of Intravenous Elemental Iron Administered
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Maintaining Iron Sufficiency (Defined as Ferritin ≥100 Nanograms Per Milliliter and Transferrin Saturation ≥20%)
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Utilizing Resources
Time frame:
up to 20 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-emergent Adverse Events

Treatment-emergent adverse events were collected in all participants enrolled in the study.

Time frame:
up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsVadadustatEpoetin Alfa
Number of Participants With Treatment-emergent Adverse Events00

Adverse events

Collected over up to Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat———
Epoetin Alfa0/2 (0%)0/2 (0%)0/2 (0%)

Baseline characteristics

All subjects enrolled in the trial.

Age, Categorical
Age, Categorical(Participants)VadadustatEpoetin AlfaTotal
<=18 years—00
Between 18 and 65 years—11
>=65 years—11
Sex: Female, Male
Sex: Female, Male(Participants)VadadustatEpoetin AlfaTotal
Female—NANA
Male—NANA
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VadadustatEpoetin AlfaTotal
American Indian or Alaska Native—NANA
Asian—NANA
Native Hawaiian or Other Pacific Islander—NANA
Black or African American—NANA
White—NANA
More than one race—NANA
Unknown or Not Reported—NANA
08

Study locations

18 sites
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Elk Grove, California 95758, United States
  • Research Site
    Encino, California 91316, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    San Diego, California 92115, United States
  • Research Site
    San Luis Obispo, California 93401, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Miami, Florida 33183, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    Statesboro, Georgia 30458, United States
  • Research Site
    Detroit, Michigan 48224, United States
  • Research Site
    Bronx, New York 10473, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    El Paso, Texas 79915, United States
  • Research Site
    Houston, Texas 77070, United States
  • Research Site
    Newport News, Virginia 23605, United States
  • Research Site
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Mar 2018, 10 months.

Results were first posted in Feb 2021, 2 years 11 months after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2017
First posted
May 4, 2017
StartActual
May 2, 2017
Primary completionActual
Mar 21, 2018
CompletionActual
Mar 21, 2018
Results delay requested
Sep 15, 2018
Results first posted
Feb 21, 2021
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03140722
Responsible party
Sponsor
First posted
May 4, 2017
Start date
May 2, 2017
Primary completion
Mar 21, 2018
Completion
Mar 21, 2018
Results posted
Feb 21, 2021
Last update
Feb 21, 2021

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion